ABT-263, a BCL-2 inhibitor, selectively eliminates latently HIV-1-infected cells without viral reactivation. Kang JE, Seo HW, Kim DE, Shin YH, et al. PLoS One 2025;20:e0322962.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Kang JE, Seo HW, Kim DE, Shin YH, et al. ABT-263, a BCL-2 inhibitor, selectively eliminates latently HIV-1-infected cells without viral reactivation. PLoS One 2025;20:e0322962.
PMID: 40392781